Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 4,986 matching trials from the live ClinicalTrials.gov search.

Filters: San Diego, California Clear all

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 34
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 18 more

Conditions: Non-small Cell Lung Cancer, Lung Cancer, Advanced Malignancies, Carcinoma
Interventions: Brigatinib; Drug
Lead sponsor: Ariad Pharmaceuticals; Industry
Eligibility: 18 Years and older
U.S. locations: 3
States / cities: La Jolla, California • Orange, California • Detroit, Michigan

Conditions: Acupuncture, Pain Management, Emergency Department, Acute Pain
Interventions: Acupuncture for pain management, Usual care for pain management; Procedure · Other
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 4
States / cities: La Jolla, California • The Bronx, New York • Cleveland, Ohio + 1 more

Conditions: Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
Interventions: Cabozantinib S-malate, Laboratory Biomarker Analysis, Sunitinib Malate; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 488
States / cities: Mobile, Alabama • Anchorage, Alaska • Burbank, California + 295 more

Conditions: Advanced Breast Cancer, Advanced Malignant Solid Tumors, Breast Neoplasms
Interventions: HKI-272, Paclitaxel; Drug
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 8
States / cities: La Jolla, California • San Diego, California • Boston, Massachusetts + 4 more

Conditions: Femur Fracture
Interventions: Ultrasound-Guided Fascia Iliaca Compartment Nerve Block; Procedure
Lead sponsor: Zachary Binder; Other
Eligibility: 4 Years to 17 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 9
States / cities: San Diego, California • San Francisco, California • Denver, Colorado + 6 more

Conditions: Infections, Pediatrics
Interventions: Ceftaroline fosamil, Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam, Cephalexin or Clindamycin or Linezolid; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 2 Months to 17 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 28
States / cities: Phoenix, Arizona • Orange, California • San Diego, California + 23 more

Conditions: MTBI - Mild Traumatic Brain Injury, Dysfunction of Vestibular System
Interventions: Conventional Therapy (CPT), CAREN Therapy, Augmented Reality (AR) Therapy; Other · Device
Lead sponsor: Naval Health Research Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: San Diego, California • Bethesda, Maryland

Conditions: Pancreatic Cancer, Adenocarcinoma
Interventions: ARQ 501 in combination with gemcitabine; Drug
Lead sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA); Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 15
States / cities: Mobile, Alabama • La Jolla, California • Rancho Mirage, California + 9 more

Conditions: Non-Hodgkin Lymphoma
Interventions: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy, Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 22
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 19 more

Conditions: Osteoarthritis
Interventions: Canakinumab, Placebo to canakinumab, Naproxen, Placebo to Naproxen; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 8
States / cities: Anniston, Alabama • Mesa, Arizona • San Diego, California + 5 more

Conditions: COVID-19 Vaccination
Interventions: FoTv; Dietary Supplement
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: Meniere's Disease
Interventions: Magnevist (gadopentetate dimeglumine); Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: San Diego, California

Conditions: Essential Tremor, Tremor
Interventions: Ethanol, Propranolol; Other · Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 21 Years and older
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Crohn's Disease
Interventions: Adalimumab, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 48
States / cities: Birmingham, Alabama • Dothan, Alabama • La Jolla, California + 41 more

Conditions: Alzheimer Disease
Interventions: Donepezil, Vitamin E; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 55 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 63
States / cities: Phoenix, Arizona • Tucson, Arizona • Irvine, California + 53 more

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Breast Carcinoma, Metastatic Breast Carcinoma
Interventions: Atezolizumab, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Positron Emission Tomography, Questionnaire Administration, X-Ray Imaging; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 58
States / cities: Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 43 more

Conditions: Vasomotor Symptoms Associated With Menopause, Hot Flashes
Interventions: Elinzanetant (BAY3427080), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 48
States / cities: Birmingham, Alabama • Mobile, Alabama • Peoria, Arizona + 43 more

Conditions: HIV Infection, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions: Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: Los Angeles, California • San Diego, California • The Bronx, New York

Conditions: Schizophrenia, Schizoaffective Disorder, Mood Disorder, Psychotic
Interventions: mobile Social Interaction Therapy by Exposure (mSITE); Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: La Jolla, California

Conditions: COVID-19, Sars-CoV-2 Infection
Interventions: NVX-CoV2705, Placebo; Biological
Lead sponsor: Novavax; Industry
Eligibility: 50 Years to 65 Years
Enrollment: 6,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 99
States / cities: Athens, Alabama • Birmingham, Alabama • Gadsden, Alabama + 88 more

Conditions: Treatment Resistant Depression
Interventions: Vagus Nerve Stimulation (VNS); Device
Lead sponsor: LivaNova; Industry
Eligibility: 18 Years and older
Enrollment: 6,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 101
States / cities: Birmingham, Alabama • Huntsville, Alabama • Burlingame, California + 85 more

Conditions: Breast Cancer, Hot Flashes, Sexual Dysfunction, Fertility, Contraception
Interventions: Reproductive Health Survivorship Care Plan (SCPR), Control; Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Physical Activity
Interventions: Digital/social media intervention; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 13 Years to 18 Years · Female only
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: La Jolla, California

Search by objective public record fields.

Discontinuation of Antiretroviral Therapy in Patients With Asymptomatic HIV Infection

An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

Acupuncture in the Emergency Department for Pain Management

Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer

Study Comparing Ultrasound-guided FICNB Block to Systemic Analgesia in Treatment of Pediatric Femur Fracture

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections

Use of Virtual and Augmented Reality Devices in Vestibular Physical Therapy for mTBI

ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee

RCT of Mushroom Based Natural Product to Enhance Immune Response to COVID-19 Vaccination

Magnetic Resonance Imaging Evaluation of Inner Ear Pathology Using Intra-Tympanic Contrast Agent

Functional Imaging of Tremor Circuits and Mechanisms of Treatment Response

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

Memory Impairment Study (Mild Cognitive Impairment Study)

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)

Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection

Context-Aware Mobile Intervention for Social Recovery in Serious Mental Illness

Efficacy and Safety of NVX-CoV2705

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

Reproductive Health Survivorship Care Plan

Physical Activity Intervention for Adolescent Girls